{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:53:48Z","timestamp":1790970828116,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-05081-0","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:14:10Z","timestamp":1783592050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of concomitant chemotherapy on edoxaban plasma concentration in patients with colorectal cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Jihyung","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Daimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9602-6659","authenticated-orcid":false,"given":"Masataka","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"5081_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"5081_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1463-1318.2008.01735.x","volume":"11","author":"W Hohenberger","year":"2009","unstructured":"Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation\u2013technical notes and outcome. Colorectal Dis. 2009;11:354\u201365. https:\/\/doi.org\/10.1111\/j.1463-1318.2008.01735.x.","journal-title":"Colorectal Dis"},{"key":"5081_CR3","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/archsurg.133.8.894","volume":"133","author":"RJ Heald","year":"1998","unstructured":"Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978\u20131997. Arch Surg. 1998;133:894\u2013849. https:\/\/doi.org\/10.1001\/archsurg.133.8.894. https\/\/.","journal-title":"Arch Surg"},{"key":"5081_CR4","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00384-021-03945-3","volume":"36","author":"R Gosavi","year":"2021","unstructured":"Gosavi R, Chia C, Michael M, Heriot AG, Warrier SK, Kong JC. Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2021;36:2063\u201370. https:\/\/doi.org\/10.1007\/s00384-021-03945-3.","journal-title":"Int J Colorectal Dis"},{"key":"5081_CR5","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3748\/wjg.v29.i10.1569","volume":"29","author":"W Leowattana","year":"2023","unstructured":"Leowattana W, Leowattana P, Leowattana T. Systemic treatment for metastatic colorectal cancer. World J Gastroenterol. 2023;29:1569\u201388. https:\/\/doi.org\/10.3748\/wjg.v29.i10.1569.","journal-title":"World J Gastroenterol"},{"key":"5081_CR6","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","volume":"125","author":"AA Khorana","year":"2010","unstructured":"Khorana AA. Venous Thromboembolism and Prognosis in Cancer. Thromb Res. 2010;125:490\u20133. https:\/\/doi.org\/10.1016\/j.thromres.2009.12.023.","journal-title":"Thromb Res"},{"key":"5081_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4251\/wjgo.v9.i9.363","volume":"9","author":"RL Metcalf","year":"2017","unstructured":"Metcalf RL, Al-Hadithi E, Hopley N, Henry T, Hodgson C, McGurk A, et al. Characterisation and risk assessment of venous thromboembolism in gastrointestinal cancers. World J Gastrointest Oncol. 2017;9:363\u201371. https:\/\/doi.org\/10.4251\/wjgo.v9.i9.363.","journal-title":"World J Gastrointest Oncol"},{"key":"5081_CR8","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1253\/circj.CJ-19-0515","volume":"83","author":"J Sakamoto","year":"2019","unstructured":"Sakamoto J, Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, et al. COMMAND VTE Registry Investigators. Cancer-Associated Venous Thromboembolism in the Real World\u3000- From the COMMAND VTE Registry. Circ J. 2019;83:2271\u201381. https:\/\/doi.org\/10.1253\/circj.CJ-19-0515.","journal-title":"Circ J"},{"key":"5081_CR9","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, ESC Scientific Document Group, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"key":"5081_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x.","journal-title":"J Thromb Haemost"},{"key":"5081_CR11","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/cpt.70129","volume":"119","author":"SC Tang","year":"2026","unstructured":"Tang SC, Lin SY, Chen CH, Liu YB, Ho LT, Kuo CH, et al. Real-world edoxaban concentrations in older patients receiving reduced-dose regimens. Clin Pharmacol Ther. 2026;119:688\u201395. https:\/\/doi.org\/10.1002\/cpt.70129.","journal-title":"Clin Pharmacol Ther"},{"key":"5081_CR12","doi-asserted-by":"publisher","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, ESC Scientific Document Group, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Supplementary data. Eur Heart J. 2022;1\u201345. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"5081_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ejca.2021.02.026","volume":"148","author":"M Verso","year":"2021","unstructured":"Verso M, Munoz A, Bauersachs R, Huisman MV, Mandal\u00e0 M, Vescovo G, et al. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. Eur J Cancer. 2021;148:371\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.026.","journal-title":"Eur J Cancer"},{"key":"5081_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12959-023-00500-8","volume":"21","author":"T Oride","year":"2023","unstructured":"Oride T, Sawada K, Shimizu A, Kinose Y, Takiuchi T, Kodama M, et al. Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study). Thromb J. 2023;21:57. https:\/\/doi.org\/10.1186\/s12959-023-00500-8.","journal-title":"Thromb J"},{"key":"5081_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.5414\/cpp39517","volume":"39","author":"M Baumh\u00e4kel","year":"2001","unstructured":"Baumh\u00e4kel M, Kasel D, Rao-Schymanski RA, B\u00f6cker R, Beckurts KT, Zaigler M, et al. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol The. 2001;39:517\u201328. https:\/\/doi.org\/10.5414\/cpp39517.","journal-title":"Int J Clin Pharmacol The"},{"key":"5081_CR16","first-page":"1205","volume":"6","author":"MA Graham","year":"2000","unstructured":"Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6:1205\u201318.","journal-title":"Clin Cancer Res"},{"key":"5081_CR17","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3390\/cancers2031717","volume":"2","author":"K Miura","year":"2010","unstructured":"Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H, et al. 5-fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers (Basel). 2010;2:1717\u201330. https:\/\/doi.org\/10.3390\/cancers2031717.","journal-title":"Cancers (Basel)"},{"key":"5081_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1124\/dmd.30.6.731","volume":"30","author":"V Charasson","year":"2002","unstructured":"Charasson V, Haaz MC, Robert J. Determination of drug interactions occurring with the metabolic pathways of irinotecan. Drug Metab Dispos. 2002;30:731\u20133. https:\/\/doi.org\/10.1124\/dmd.30.6.731.","journal-title":"Drug Metab Dispos"},{"key":"5081_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","volume":"9","author":"L Liu","year":"2018","unstructured":"Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2018;9:15\u201332. https:\/\/doi.org\/10.1007\/s13238-017-0408-4.","journal-title":"Protein Cell"},{"key":"5081_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.resinv.2020.11.007","volume":"59","author":"T Hotta","year":"2021","unstructured":"Hotta T, Tsubata Y, Hamai K, Tanino A, Kobayashi M, Nakamura A, et al. Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism. Respir Investig. 2021;59:327\u201334. https:\/\/doi.org\/10.1016\/j.resinv.2020.11.007.","journal-title":"Respir Investig"},{"key":"5081_CR21","doi-asserted-by":"publisher","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Hokusai VTE Cancer Investigators. (2018). Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615\u2013624. https:\/\/doi.org\/10.1056\/NEJMoa1711948.","DOI":"10.1056\/NEJMoa1711948"},{"key":"5081_CR22","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1055\/s-0038-1667001","volume":"118","author":"N Kraaijpoel","year":"2018","unstructured":"Kraaijpoel N, Di Nisio M, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018;118:1439\u201349. https:\/\/doi.org\/10.1055\/s-0038-1667001.","journal-title":"Thromb Haemost"},{"key":"5081_CR23","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/1078155216631408","volume":"23","author":"A Dushenkov","year":"2017","unstructured":"Dushenkov A, Kalabalik J, Carbone A, Jungsuwadee P. Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice. J Oncol Pharm Pract. 2017;23:296\u2013308. https:\/\/doi.org\/10.1177\/1078155216631408.","journal-title":"J Oncol Pharm Pract"},{"key":"5081_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/15360288.2023.2301341","volume":"38","author":"K Makihara","year":"2024","unstructured":"Makihara K, Yamamoto Y, Miyazaki M, Taguchi M, Sato J, Takase H, et al. A multicenter retrospective observational study analyzing the effect of polypharmacy on oxycodone tolerability. J Pain Palliat Care Pharmacother. 2024;38:3\u201312. https:\/\/doi.org\/10.1080\/15360288.2023.2301341.","journal-title":"J Pain Palliat Care Pharmacother"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05081-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05081-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05081-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:02:00Z","timestamp":1790967720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-05081-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5081"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05081-0","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol was carried out in accordance with the tenets stipulated in the Declaration of Helsinki, Japanese ethical guidelines on clinical research, and Ethical Guidelines for Clinical Studies. The study was registered with the University Hospital Medical Information Network Clinical Trials Registry (protocol ID: 000043850). The study protocol was reviewed and approved by the Hyogo Medical University Clinical Research Review Committee (protocol ID: 3676) on December 21, 2020. All patients provided written informed consent. The institutional review board at each participating center approved the protocol.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"603"}}